Related Experiment Video
Updated: Jan 6, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
Xavier Paliard1, Olivier Rixe2
1Personalis Inc., Menlo Park, CA, USA. xavier.paliard@personalis.com.
Abstract:
The clinical development of cancer drugs is rapidly moving from empirical "one drug fits all" or development-by-tumor-type approaches towards more personalized treatment models. A deeper understanding of cancer and the immune system, novel technologies, and powerful analytics have fueled an increase in precision oncology approaches integrating the molecular profiles of the tumor with the clinical profile of the patient. While this approach has been successful for targeted therapies, the complex mode of action of immunotherapies will likely require integration of clinical profiling with more comprehensive profiling of the tumor, of the tumor microenvironment, and of the immune system of the patient. Integration of precision oncology into clinical research for immunotherapies is viewed as a means to better select patients in the early clinical phase of drug development to (1) maximize the benefit-to-risk ratio for the patient, (2) generate early proof of concept and proof of relevance for the investigational drug, and (3) inform on how to best combine or sequence the therapeutic with other drugs. Here we discuss the upsides and challenges of incorporating precision immuno-oncology into early-phase clinical trials.
Insights
Precision immuno-oncology integrates patient molecular and clinical profiles for cancer drug development. This approach enhances early clinical trials by optimizing patient selection and drug efficacy.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Cancer drug development is shifting from broad approaches to personalized medicine.
- Precision oncology integrates tumor molecular profiles with patient clinical data.
- Immunotherapies require more comprehensive profiling beyond current precision oncology models.
Purpose of the Study:
- To explore the integration of precision oncology into early-phase clinical trials for immunotherapies.
- To discuss the benefits and challenges of precision immuno-oncology in early drug development.
- To highlight how precision immuno-oncology can improve patient selection and drug development outcomes.
Main Methods:
- Review of current trends in precision oncology and immunotherapy development.
- Analysis of the requirements for comprehensive profiling in immunotherapy trials.
- Discussion of strategies for integrating molecular, tumor microenvironment, and immune system data.
Main Results:
- Precision immuno-oncology offers significant advantages for early-phase clinical trials.
- Enhanced patient selection can maximize benefit-to-risk ratios and generate early proof of concept.
- Comprehensive profiling is crucial for understanding immunotherapy mechanisms and optimizing combinations.
Conclusions:
- Integrating precision oncology with comprehensive profiling is essential for advancing immunotherapy development.
- Precision immuno-oncology holds the potential to accelerate the delivery of effective cancer treatments.
- Addressing the challenges of precision immuno-oncology will be key to realizing its full potential.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers